The CDK2, 7 and 9 genes are frequently upregulated in GBM patients compared to non-tumour tissue [27] and thus establishes a therapeutic rationale for targeting these CDKs specifically, using transcriptional CDK inhibitors, CYC065 (CDK2/9i) and THZ1 (CDK7i). This evidence concerns the gene CDK2 and glioblastoma.